Explanipedia

MECOM amplified endometrial cancer, a novel subset of copy number high tumors associated with poor prognosis Open

J. Romaní, Aminah Jatoi, Andrea Mariani, William A. Cliby, Jamie N. Bakkum‐Gamez , et al. · 2025

Objective: Copy number high (CNH) endometrial cancer (EC) is an aggressive molecular subgroup characterized by TP53 mutations and relative chemoresistance. CNH EC with cyclin E1 gene (CCNE1) amplification and erythroblastic oncogene B (ERB…

Management of significant pleural effusion at ovarian cancer diagnosis: Outcomes of triage to neoadjuvant chemotherapy without thoracic assessment Open

Stuart A. Ostby, Chiara Ainio, Conway Xu, Kelly H. Bruce, Matthew S. Block , et al. · 2025

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update Open

Stéphanie Gaillard, Christina Lacchetti, Deborah K. Armstrong, William A. Cliby, Mitchell I. Edelson , et al. · 2025

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Gui…

Abstract #42: Real-world outcomes of neoadjuvant chemotherapy for ovarian cancer: What happens to patients who never undergo surgery? Open

Kelly H. Bruce, Conway Xu, Rushi Shah, Michaela McGree, Angela J. Fought , et al. · 2024

Exploring global barriers to optimal ovarian cancer care: thematic analysis Open

Selina Sfeir, Lucy Allen, Marc Daniël Algera, R. Hugh Morton, Rhonda Farrell , et al. · 2024

Understanding the patient experience in nonsurgical management of endometrial cancer and complex atypical hyperplasia due to obesity: A qualitative analysis Open

Aparna Kailasam, Aminah Jatoi, Evelyn Reynolds, William A. Cliby, Carrie Langstraat · 2024

The themes identified in the present study highlight the challenges and the stigma these patients face. It also demonstrates areas of opportunity in their counseling and care, which will help to build a more effective therapeutic relations…

Surgical training of gynecologic oncology fellows: Long-term trends and implications for future education Open

Mitchel S. Hoffman, Victoria Dunsmore, William A. Cliby, Dennis Chi, Stephanie B. Wheeler , et al. · 2024

Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease Open

Dhanya Ramachandran, Jonathan P. Tyrer, Stefan Kommoss, Anna deFazio, Marjorie J. Riggan , et al. · 2024

Cost-effectiveness analysis of margin-controlled surgery for vulvar Paget’s disease Open

Kelly H. Bruce, James P. Moriarty, Bijan J. Borah, Ruchita Dholakia, Mary E. Lohman , et al. · 2024

MMS-E appears to be a cost-effective treatment for vulvar Paget's disease compared to historic standard of care. Our ability to estimate quality of life gained by avoiding disease recurrence was limited by scant data for this rare conditio…

Defining Optimal Perioperative Analgesia in Patients Undergoing Laparotomy for Advanced Gynecologic Malignancy: A Randomized Controlled Trial Open

Stuart A. Ostby, Deepa Maheswari Narasimhulu, Michelle A. O. Kinney, William A. Cliby, Carrie Langstraat , et al. · 2024

Textbook Oncologic Outcome is an Easy-to-Use Composite Quality Measure that is Strongly Associated with Survival in Advanced-Stage Ovarian Cancer Open

Giuseppe Caruso, Carrie Langstraat, Amanika Kumar, Michaela E. McGree, Angela J. Fought , et al. · 2024

Table of Contents Open

David R. Nelson, Christina L. Herrera, Donald D. McIntire, Eve Espey, Stephanie Teal , et al. · 2023

EP292/#701 Revisiting the role of interval cytoreductive surgery (ICS) following neoadjuvant chemotherapy (NACT) for patients with advanced stage epithelial ovarian cancer; a multicenter database analysis Open

Dimitrios Nasioudis, Nawar Latif, Emily Ko, Stefan M. Gysler, Lori Cory , et al. · 2023

Introduction Investigate the role ICS for ovarian cancer patients receiving NACT. Methods Patients diagnosed between 2010–2015 with stage III-IV ovarian carcinoma who received NACT and ICS with known status of residual disease were identif…

Nonsurgical management of early-stage endometrial cancer due to obesity: a survey of the practice patterns of current Society of Gynecologic Oncology members Open

Aparna Kailasam, Giuseppe Cucinella, Angela J. Fought, William A. Cliby, Andrea Mariani , et al. · 2023

Not all endometrial clear cell carcinomas are created equal (2257) Open

Fiorella E. Reyes-Baez, Maryam Shahi, Michaela E. McGree, Angela J. Fought, Gabriella Schivardi , et al. · 2023

Endometrial cancer and the obesity conundrum: A survey of the practice patterns of current SGO members (2187) Open

Aparna Kailasam, Giuseppe Cucinella, Angela J. Fought, William A. Cliby, Andrea Mariani , et al. · 2023

Mohs surgery for female genital Paget’s disease: a prospective observational trial Open

Kelly H. Bruce, Toni P. Kilts, Mary E. Lohman, Nahid Y. Vidal, Angela J. Fought , et al. · 2023

Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon? Open

Giuseppe Caruso, Robert L. Coleman, Giovanni Aletti, Francesco Multinu, Andrea Botticelli , et al. · 2023

14 Prognostic role of the molecular classification in endometrial cancer patients with cervical stromal invasion Open

Fiorella E. Reyes-Baez, Gabriella Schivardi, Luigi Antonio De Vitis, Maryam Shahi, Michaela E. McGree , et al. · 2023

Cervical stromal invasion (CSI) in endometrial cancer (EC) is rare, but it is a sign of a disease that is either biologically aggressive, or a tumor that grew for a significant time in patients who had delayed medical care. The optimal tre…

Muscle loss during cancer therapy is associated with poor outcomes in advanced ovarian cancer Open

Clarissa Polen-De, Smith Giri, Priyal Fadadu, Amy L. Weaver, Michaela E. McGree , et al. · 2023

Data evaluating change in body composition during treatment of advanced cancer are limited. Here we evaluated computed tomography (CT)–based changes in muscle mass during treatment for advanced ovarian cancer (OC) and association with outc…

Data from Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer Open

Gottfried E. Konecny, Boris Winterhoff, Teodora Kolarova, Jingwei Qi, Kanthinh Manivong , et al. · 2023

Purpose: PD-0332991 is a selective inhibitor of the CDK4/6 kinases with the ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. Here we investigate the role of CDK4/6 inhibition in human ovarian cancer.<…

Data from Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer Open

Gottfried E. Konecny, Boris Winterhoff, Teodora Kolarova, Jingwei Qi, Kanthinh Manivong , et al. · 2023

Purpose: PD-0332991 is a selective inhibitor of the CDK4/6 kinases with the ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. Here we investigate the role of CDK4/6 inhibition in human ovarian cancer.<…

Supplementary Index from Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes Open